Physician profile
Aleta B Gong
NPI 1003887944
$7,269.04
in general payments reported to CMS, 2019-2025
25 companies · $885 in 2025
The $885 reported for 2025 was more than what 94% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,912 · 2020: $411 · 2021: $957 · 2022: $1,272 · 2023: $976 · 2024: $857 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.58 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,391.92 | 2019-2025 | Bromsite, Xelpros, Cequa |
| Bausch & Lomb Americas INC. | $1,377.35 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $889.37 | 2019-2021 | |
| Alcon Vision LLC | $397.15 | 2019-2024 | Hydrus Microstent, Precision 1, Total30 |
| Synergeyes, INC. | $367.85 | 2019 | |
| Coopervision INC. | $362.55 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Optos, INC. | $341.20 | 2019 | |
| Allergan, INC. | $303.03 | 2019-2022 | |
| Oyster Point Pharma, INC. | $301.86 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $253.09 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $209.62 | 2021-2022 | |
| Dompe US, INC. | $176.40 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $170.30 | 2025 | Xdemvy |
| Shire North American Group INC | $167.60 | 2019 | |
| Sight Sciences, INC. | $154.08 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $146.22 | 2019 | |
| Ivantis, INC | $93.00 | 2021 | |
| Abb Con-Cise Optical Group LLC | $38.33 | 2023 | Spectacle Lenses, Contact Lens |
| Thea Pharma INC. | $32.04 | 2022-2023 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $31.63 | 2021-2023 | Acuvue |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Topcon Healthcare, INC. | $16.64 | 2025 | |
| Maculogix, INC. | $10.34 | 2021 | |
| Travere Therapeutics, INC. | $0.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleta Gong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.